康希諾AH股均漲超10% 霧化吸入式新冠疫苗正申請緊急使用
格隆匯6月7日丨港A兩地的疫苗股集體走強,其中,康希諾AH盤中均漲超10%,A股最高漲至628元,創上市新高;H股最高漲至355港元。中國工程院院士陳薇在6月3日舉行的浦江論壇上表示,鼻噴霧式/吸入型新冠疫苗正在申請緊急使用。同時表示鼻噴霧式吸入新冠疫苗所需的劑量是皮下注射疫苗的1/5。6月2日,康希諾董事長兼CEO宇學峯在青島的一次會議上表示,康希諾的鼻噴霧式/吸入型新冠疫苗現已進入二期臨牀試驗。


Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.